{
    "nctId": "NCT04705883",
    "briefTitle": "Vaginal Prasterone In Vaginal Atrophy In Breast Cancer Survivors",
    "officialTitle": "Vaginal Prasterone In The Treatment Of Vaginal Atrophy In Patients With Breast Cancer Treatment With Aromatase Inhibitors (Vibra Study)",
    "overallStatus": "COMPLETED",
    "conditions": "Vulvar Atrophy, Breast Cancer, Genitourinary Syndrome of Menopause",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "NA",
    "primaryPurpose": "OTHER",
    "enrollmentCount": 10,
    "primaryOutcomeMeasure": "Estradiol",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Breast cancer treated with anti-hormonal therapy based on inhibitors of aromatase (IA) (letrozole, anastrozole or exemestane) \u00b1 analogues of the GnRH (aGnRH)\n* Menopause (natural or induced) and signs / symptoms of vulvovaginal atrophy\n* Cytology and / or determination of Human Papillomavirus (HPV) negative\n* Intention or willingness to have sex\n\nExclusion Criteria:\n\n* To have received topical hormonal treatment in the last 6 months or Have used vaginal moisturizers and / or lubricants during the 30 days prior to the study treatment\n* To have received treatment with laser, radiofrequency, hyaluronic acid, etc. in the vagina during the last two years at the beginning of the study\n* To Have: an active infection of the genital tract; an intraepithelial neoplasm of the cervix, vagina or vulva; suspected of suffering or having been treated for cancer of the genital tract; suffer a genital prolapse of II degree or greater",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}